簡介
黃豔娟,太阳集团1088vip,副教授,碩導。2020年畢業于太阳集团1088vip,獲藥劑學博士學位(碩博連讀)。先後主持國家自然基金青年項目、廣東省自然科學基金-青年提升項目、廣東省自然科學基金面上項目、廣東省區域聯合基金-青年基金、中國博士後基金面上項目、廣州市青年博士啟航項目、中山大學青年教師培育項目共7項課題。研究成果共發表SCI論文30餘篇,其中以第一作者/通訊作者(含共同)先後在Nat Commun、J Control Release、Acta Pharm Sin B、Biomaterials、ACS Nano、Chem Eng J、Asian J Pharm Sci、Int J Pharmaceut、Nanoscale等國内外知名學術刊物發表論文15篇,其中11篇IF>10。申請發明專利5項,其中4項已授權。擔任ACS Appl. Mater. Interfaces、Int. J. Pharmaceut.、Acta Biomater.、Acs omega、Int J Biol Macromol等期刊審稿人。Chinese chemical letters雜志青年編委,pharmaceutics 雜志特刊主題"ROS-Mediated Nano Drug Delivery for Antitumor Therapy"客座編輯(歡迎投稿,截稿日期2025.02.28).
研究方向
創新藥物制劑(包括智能響應水凝膠遞藥系統,基于幹細胞/免疫細胞的仿生型遞藥系統,腫瘤靶向智能藥物遞送與控釋系統)的開發及其在臨床重大疾病中的預防與治療應用。
主持科研項目
(1)國家自然科學基金青年基金,82104077/H3408,2022.01至2024.12,30萬,主持;
(2)廣東省自然科學基金-青年提升, 2024A1515030081,2024.01 - 2026.12,30萬,主持;
(3)廣東省自然科學基金-面上項目,2021A1515010475,2021.01至2023.12,10萬,主持;
(4)廣東省區域聯合基金-青年基金,2020A1515110305,2020.10至2023.06,10萬,主持;
(5)中國博士後科學基金面上項目,2020M683145,2020.11至2023.06,8萬,主持;
(6)廣州市基礎與應用基礎研究-青年博士“啟航”項目, 2024A04J4148,2024.01-2025.12,5萬,主持;
(7)中山大學青年教師培育項目,22qntd4505,2022.01至2023.06,5.9萬,主持。
代表性成果
- Y. Huang, Z. Guan, X. Dai, Y. Shen, Q. Wei, L. Ren, J. Jiang, Z. Xiao, Y. Jiang, D. Liu, Z. Huang, X. Xu, Y. Luo, C. Zhao*. Engineered macrophages as near-infrared light activated drug vectors for chemo-photodynamic therapy of primary and bone metastatic breast cancer, Nature Communications, 12(1), (2021), 1-22.(中科院1區Top,IF: 17.694)
- Y. Huang#, X. Dai#, Y. Gong#, L. Ren, Y. Luo, Y. Sun, M. Chen, J. Jiang, Z. Guan, C. Zhao*, ROS-responsive sprayable hydrogel as ROS scavenger and GATA6+ macrophages trap for the prevention of postoperative abdominal adhesions, Journal of Controlled Release, 369 (2024) 573-590. (中科院1區Top,IF: 10.8)
- T. Zhang#, Y. Huang#(共一第二), Y. Gong#, X. Shi, D. Xiao, L. Ren, X. Dai, Z. Zeng, C. Zhao*, A ROS-responsive and scavenging hydrogel for postoperative abdominal adhesion prevention, Acta Biomaterialia, 2024, publish online.(中科院1區Top,IF: 9.4)
- Y. Huang#, Z. Guan#, Lingling Ren#, Y. Luo, M. Chen, Y. Sun, Y. He, Z. Zeng, X. Dai, J. Jiang, Z. Huang, C. Zhao*. Bortezomib prodrug catalytic nanoreactor for chemo/chemodynamic therapy and macrophage re-education, Journal of Controlled Release, 350, (2022), 332-349.(中科院1區Top,IF: 11.467)
- J. Chen#, X. Tan#, Y. Huang#, *(共一第三,共通訊), C. Xu, Z. Zeng, T. Shan, Z. Guan, X. Xu, Z. Huang, C. Zhao*. Reactive oxygen species-activated self-amplifying prodrug nanoagent for tumor-specific Cu-chelate chemotherapy and cascaded photodynamic therapy, Biomaterials, 284, (2022) 121513.(中科院1區Top,IF: 15.304)
- Y. Huang#, Z. Xiao#, Z. Guan, Y. Shen, Y. Jiang, X. Xu, Z. Huang, C. Zhao*. A light-triggered self-reinforced nanoagent for targeted chemo-photodynamic therapy of breast cancer bone metastases via ER stress and mitochondria mediated apoptotic pathways, Journal of Controlled Release, 319, (2020), 119-134.(中科院1區Top,IF: 11.467)
- Y. Huang, Z. Xiao, Z. Guan, Z. Zeng, Y. Shen, X. Xu, C. Zhao*. Bone-seeking nanoplatform co-delivering cisplatin and zoledronate for synergistic therapy of breast cancer bone metastasis and bone resorption, Acta Pharmaceutica Sinica B, 10(12), (2020), 2384-2403.(中科院1區Top,IF: 14.903)
- Y. Huang#, Y. Jiang#, Z. Xiao#, Y. Shen, L. Huang, X. Xu, G. Wei, C. Xu, C. Zhao*. Three birds with one stone: A ferric pyrophosphate based nanoagent for synergetic NIR-triggered photo/chemodynamic therapy with glutathione depletion, Chemical Engineering Journal, 380, (2020), 122369.(中科院1區Top,IF: 16.744)
- Y. Huang#, H. Lai#, J. Jiang#, X. Xu, Z. Zeng, L. Ren, Q. Liu, M. Chen, T. Zhang, X. Ding, C. Zhao, S. Cui*. pH-activatable oxidative stress amplifying dissolving microneedles for combined chemo-photodynamic therapy of Melanoma, Asian Journal of Pharmaceutical Sciences, 17, (2022), 679-696.(中科院1區Top,IF: 9.273)
- Y. Huang#, T. Zhang#, Q. Wei#, Z. Zeng, Y. Gong, X. Xu, M. Chen, C. Zhao*. “NIR-triggered ROS storage” photodynamic intraocular implant for high-efficient and safe posterior capsular opacification prevention, Asian Journal of Pharmaceutical Sciences, 17(6), (2022), 838-854.(封面論文,中科院1區Top,IF: 9.273)
- Y. Huang#, X. Dai#, Z. Guan#, D. Liu, L. Ren, M. Chen, Z. Zeng, J. Jiang, Y. Luo, Y. He, M. Huang, C. Zhao*. A DNA damage nanoamplifier for the chemotherapy of triple-negative breast cancer via DNA damage induction and repair blocking, International journal of pharmaceutics, 622, (2022), 121897(藥學2區Top,IF: 6.51)
- Y. Huang#, Y. He#, Z. Huang, Y. Jiang, W. Chu, X. Sun, L. Huang, C. Zhao*. Coordination self-assembly of platinum-bisphosphonate polymer-metal complex nanoparticles for cisplatin delivery and effective cancer therapy. Nanoscale, 9 (28), (2017), 10002-10019.(中科院2區Top,IF: 8.307)
- J. Jiang#, Y. Huang#(共一第二), Z. Zeng and C. Zhao*. Harnessing Engineered Immune Cells and Bacteria as Drug Carriers for Cancer Immunotherapy, ACS Nano, 17, (2023), 843–884.(中科院1區Top,IF: 18.027)
- Y. He#; Y. Huang#(共一第二), Z. Huang, Y. Jiang, X. Sun, Y. Shen, W. Chu, C. Zhao*, Bisphosphonate-functionalized coordination polymer nanoparticles for the treatment of bone metastatic breast cancer. Journal of Controlled Release, 264, (2017), 76-88.(中科院1區Top,IF: 11.467)
- W. Chu#, Y. Huang#(共一第二), C. Yang, Y. Liao, X. Zhang, M. Yan, S. Cui, C. Zhao*. Calcium phosphate nanoparticles functionalized with alendronate-conjugated polyethylene glycol (PEG) for the treatment of bone metastasis. International journal of pharmaceutics, 516 (1-2), (2017), 352-363.(藥學2區Top,IF: 6.51)
- Z. Huang, Y. Huang(第二作者), M. Chen, J. Chen, Z. Zeng, X. Xu, B. Huang, Y. Luo, Z. Xiao, Y. Ding, Bone-targeted oxidative stress nanoamplifier for synergetic chemo/chemodynamic therapy of bone metastases through increasing generation and reducing elimination of ROS, Chemical Engineering Journal 399 (2020) 125667(中科院1區Top,IF: 16.744).
- 黃豔娟,趙春順,關梓琳。一種近紅外光激活型巨噬細胞-納米前藥靶向遞藥系統的構建及其應用,專利号:202110760793.7,發明授權